| amphotericin b liposome / Generic mfg. |
2018-000972-14: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded). |
|
|
| Not yet recruiting | 3 | 224 | Europe | Ambisome®, Sporanox®, Vfend®, NOXAFIL, Powder for solution for infusion, Capsule, Tablet, Ambisome®, Sporanox®, Vfend®, NOXAFIL | CHU DE POITIERS, DGOS, JASSEN, MSD-MERCK, PFIZER, ELIVIE, SOS-Oxygen, VIVISOL, ORHE PHARMA | Chronic Pulmonary Aspergillosis, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | | | | |
2016-002335-14: A ß-d-glucan guided antifungal stewardship strategy for the management of patients with severe abdominal sepsis. A multicenter interventional explorative study with a pharmadynamic/pharmachokinetic substudy entitled: “A Pilot substudy of Liposomal Amphotericin B Pharmacodynamics in Patients with Abdominal Sepsis” conducted only in the coordinating center Strategia di gestione antimicotica guidata dal ß -d-glucano per pazienti con sepsi addominale grave. Studio interventistico multicentrico esplorativo con sottostudio di farmacocinetica/farmacodinamica intitolato: “Sottostudio pilota di farmacodinamica di amfotericina B liposomiale in pazienti con sepsi addominale” che verrà condotto solo nel centro coordinatore |
|
|
| Ongoing | 3 | 40 | Europe | AmBisome, [AmBisome], Powder for solution for infusion, AMBISOME - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, Gilead | Patients with severe sepsis or septic shock Pazienti con patologia chirurgica addominale severa; Pazienti con sepsi grave o shock settico, Patients with severe sepsis or septic shock Pazienti con patologia chirurgica addominale severa; Pazienti con sepsi grave o shock settico, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2021-000386-32: A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis. Estudio para evaluar la eficacia y seguridad de olorofim en comparación con AmBisome® para el tratamiento de la aspergilosis invasiva. |
|
|
| Not yet recruiting | 3 | 225 | Europe | olorofim, AmBisome, F901318, Film-coated tablet, Powder for concentrate for dispersion for infusion, AmBisome | F2G Ltd., F2G Ltd. | invasive fungal infections due to Aspergillus spp. infecciones fúngicas invasivas debidas a Aspergillus spp., invasive fungal infections infecciones fúngicas invasivas, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT05108545: A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever |
|
|
| Not yet recruiting | 3 | 93 | NA | Amphotericin B liposomes | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Neutropenia and Fever | 07/22 | 01/23 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Recruiting | 2/3 | 356 | RoW | Single dose liposomal Amphotericin and Fluconazole, AMBISOME and fluconazole, Fluconazole | Makerere University, University of Minnesota, Gilead Sciences | Cryptococcal Meningitis | 10/27 | 04/28 | | |
NCT05593666: A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis |
|
|
| Recruiting | 2 | 105 | RoW | LXE408, Placebo, AmBisome® | Drugs for Neglected Diseases, Novartis Pharmaceuticals | Primary Visceral Leishmaniasis | 01/25 | 01/25 | | |
NCT05749380: Pharmacokinetics and Safety of AmBisome and DKF-5122 |
|
|
| Completed | 1 | 38 | RoW | AmBisome, DKF-5122 | Dongkook Pharmaceutical Co., Ltd. | Invasive Fungal Infections, Neutropenic Fever | 01/22 | 01/22 | | |
NCT05913921: Bioequivalence of Amphotericin B Liposome for Injection |
|
|
| Completed | 1 | 32 | RoW | Amphotericin B liposome for injection, the test product, AmBisome, the reference product | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Bioequivalence | 09/23 | 09/23 | | |